Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 20, 2011

View Archived Issues

Phase II trial evaluates dutasteride in spinal and bulbar muscular atrophy / News in Context

Russian scientists claim new melanocortin MC2 receptor ligands

DA-1229 may be beneficial in diabetes types 1 and 2

Talactoferrin increases survival of patients with septic shock and systolic dysfunction

Ironwood Pharma and Protagonist Therapeutics join to develop new peptide therapeutics

MAb 1C11 impairs growth of S. aureus and may be candidate drug for MRSA-associated osteomyelitis

Therapure Biopharma describes hemoglobin-drug conjugates for targeted delivery to the liver

Zalicus provides update on product candidates and collaborations

Cadence Pharma launches Ofirmev in U.S. for pain and fever

Johns Hopkins Brain Science Institute and Ortho-McNeil-Janssen enter collaboration

New inhibitors claimed of Egl nine homolog 1, 2 and 3

Dainippon Sumitomo claims new dopamine D2 receptor ligands

New inhibitors of JAK1, JAK2 and JAK3 developed at Genentech

Targacept reports phase II data on TC-5619 in schizophrenia

Ono Pharmaceutical divulges new chymase inhibitors

DWTI identifies new substituted isoquinoline derivatives

UCB provides update on development milestones

Ono Pharma claims new agents for urinary incontinence

Alexza completes end-of-review meeting with FDA regarding AZ-004

GSK-2402968 enters phase III trial in Duchenne's muscular dystrophy

PROLOR and Yeda sign agreement for reversible PEGylation technology

Harbor BioSciences licenses three compounds to CIPI in China

Zanamivir enters phase III trial in hospitalized patients with influenza

FDA issues complete response letter to MannKind regarding Afrezza NDA

Lundbeck begins phase III program for zicronapine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...